Browse EX-10 agreements

TWENTIETH AMENDMENT TO THE
RECEIVABLES PURCHASE AGREEMENT

This TWENTIETH AMENDMENT TO THE RECEIVABLES PURCHASE AGREEMENT (this “Amendment”), dated as of July 10, 2026, is entered into by and among the following parties:

(i)TRANSDIGM RECEIVABLES LLC, a Delaware limited liability company, as Seller;

(ii)TRANSDIGM INC., a Delaware corporation, as Servicer;

(iii)PNC BANK, NATIONAL ASSOCIATION, as a Committed Purchaser, as Purchaser Agent for its Purchaser Group and as Administrator (“PNC”); and

(iv)WELLS FARGO BANK, NATIONAL ASSOCIATION (“Wells Fargo”), as a Committed Purchaser and as Purchaser Agent for its Purchaser Group.

(v)Capitalized terms used but not otherwise defined herein (including such terms used above) have the respective meanings assigned thereto in the Receivables Purchase Agreement described below.

BACKGROUND

…

Syndax Pharmaceuticals, Inc.
RSU Award Grant Notice
(2026 Equity Incentive Plan)

Syndax Pharmaceuticals, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan (the “Plan”) and the Award Agreement (the “Agreement”), which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.

Participant:

Date of Grant:

Vesting Commencement Date:

Number of Restricted Stock Units:

…

Syndax Pharmaceuticals, Inc.
RSU Award Grant Notice
(2026 Equity Incentive Plan)

Syndax Pharmaceuticals, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan (the “Plan”) and the Award Agreement (the “Agreement”), which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.

Participant:

Date of Grant:

Vesting Commencement Date:

Number of Restricted Stock Units:

Vesting Schedule:[____________________________________________________________].

Notwithstanding the foregoing, vesting shall terminate upon the Participant’s termination of Continuous Service.

…

Syndax Pharmaceuticals, Inc.
Stock Option Grant Notice
(2026 Equity Incentive Plan)

Syndax Pharmaceuticals, Inc. (the “Company”), pursuant to the Company’s 2026 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”)an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.

…

OFFICE LEASE

Between

DE PARK AVENUE 1100, LLC,

a Delaware limited liability company

as Landlord

and CHROMADEX, INC.,

a California corporation as Tenant

June 12, 2026

---

OFFICE LEASE

BASIC LEASE INFORMATION (“BLI”)

Dated as of:					June 12, 2026
“Landlord”:					DE PARK AVENUE 1100, LLC,a Delaware limited liability company
“Tenant”:					CHROMADEX, INC.,a California corporation

SECTION

1.1    “Premises”:    Suite Number:    1800

Floor:    Eighteenth (18th)

“Building”:    1100 Glendon Avenue

Los Angeles, California 90024

1.4    “Rentable Area” of the Premises:    10,564 square feet

1.4    “Usable Area” of the Premises:    8,384 square feet

…

PACS GROUP, INC.2024 INCENTIVE AWARD PLAN

RESTRICTED STOCK UNIT GRANT NOTICE (DIRECTOR ANNUAL AWARDS)

PACS Group, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of the PACS Group, Inc. 2024 Incentive Award Plan (as amended from time to time, the “Plan”) and the Restricted Stock Unit Agreement attached hereto as Exhibit A(the “Agreement”), both of which are incorporated into this Grant Notice by reference. Capitalized terms not specifically defined in this Grant Notice or the Agreement have the meanings given to them in the Plan.

…

PACS GROUP, INC.

AMENDED AND RESTATED

NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM

Eligible Directors (as defined below) on the board of directors (the “Board”) of PACS Group, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically as set forth herein and without further action of the Board, to each member of the Board who is not an employee of the Company or any of its parents or subsidiaries unless such member is determined by the Board to not be eligible to receive compensation under this Program (each, an “Eligible Director”) unless such Eligible Director declines the receipt of such cash or equity compensation by written notice to the Company.

…

ARROWHEAD PHARMACEUTICALS, INC.

AMENDED AND RESTATED 2021 INCENTIVE PLAN

1. DEFINED TERMS

Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms.

2. PURPOSE

The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other incentive Awards.

3. ADMINISTRATION

…

THIRD AMENDMENT TO OFFICE LEASE

This THIRD AMENDMENT TO OFFICE LEASE(“Third Amendment”) is made and entered into on the 27th day of April, 2026 (the “Effective Date”), by and between 177 COLORADO OWNER LLC, a Delaware limited liability company(“Landlord”), and ARROWHEAD PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

R E C I T A L S :

A.    Landlord and Tenant entered into that certain Office Leasedated as of April 17, 2019 (the “Original Lease”), as amended by that certain Notice of Lease Term Dates dated as of October 22, 2019 (the “2019 Commencement Memo”), that certain First Amendment to Office Lease dated as of October 23, 2020 (the “First Amendment”), that certain Notice of Lease Term Dates dated as of June 17, 2021 (the “2021 Commencement Memo”), that certain letter agreement dated as of March 9, 2023 (the “Letter Agreement”), and that certain Second Amendment to Office Lease dated as of April 12, 2023 (the “Second Amendment”, and together with the Original Lease, the 2019 Commencement Memo, the First Amendment, the 2021 Commencement Memo, and the Letter Agreement

…

[***] = CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT

License Agreement

By and Between

Arrowhead Pharmaceuticals, Inc.

and

Madrigal Pharmaceuticals, Inc.

May 4, 2026

i

---

[***] = CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT

LICENSE AGREEMENT

…

ARROWHEAD PHARMACEUTICALS, INC.
AMENDED AND RESTATED INDUCEMENT PLAN

1.DEFINED TERMS

Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms.

2.PURPOSE

The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other incentive Awards. Each Award granted under the Plan is intended to qualify as an employment inducement award pursuant to Nasdaq Listing Rule 5635(c)(4), and shall be interpreted and administered accordingly.

3.ADMINISTRATION

…

ARCHER-DANIELS-MIDLAND COMPANY

2020 INCENTIVE COMPENSATION PLAN

(As Amended May 7, 2026)

Article 1. Establishment, Objectives, and Duration

1.1. Establishment of the Plan. Archer-Daniels-Midland Company, a Delaware corporation (hereinafter referred to as the “Company”), hereby establishes an incentive compensation plan to be known as the “Archer-Daniels-Midland Company 2020 Incentive Compensation Plan” (hereinafter referred to as the “Plan”), as set forth in this document. The Plan permits the grant of various forms of equity- and cash-based Awards. The Plan shall become effective on the date it is approved by the Company’s stockholders, which shall be considered the date of its adoption for purposes of Treasury Regulation §1.422-2(b)(2)(i) (the “Effective Date”), and shall remain in effect as provided in Section 1.3 hereof. No Awards shall be made under the Plan prior to the Effective Date. If the Company’s shareholders fail to approve the Plan by May 31, 2021, the Plan will be of no further force or effect.

…